Steve Whipkey

Experience

• 

  Novartis Pharmaceuticals

  Jul 1998 - Apr 2008

  In a leadership role within a $49.1B pharmaceutical company, I executed brand-aligned growth strategies through field teams, ensuring consistent performance at or above projections for a $200M P&L. I orchestrated a successful co-promotion with Procter & Gamble, overseeing all field-facing activities.𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:✔ Masterminded Novartis' top-performing Enablex marketing campaign, generating substantial gains and winning a coveted Marketing Excellence Award. Show less

  • 𝗔𝘀𝘀𝗼𝗰𝗶𝗮𝘁𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿, 𝗘𝗻𝗮𝗯𝗹𝗲𝘅 𝗠𝗮𝗿𝗸𝗲𝘁𝗶𝗻𝗴 (Leadership Development)

    Jan 2006 - Apr 2008

  • Associate Director, Management & Leadership Training and Development

    Jan 2005 - Dec 2005

  • District Sales Manager

    Sept 2000 - Jan 2005

  • Territory Sales Representative

    Jul 1998 - Sept 2000
• 

  Sunovion Pharmaceuticals

  Apr 2008 - Dec 2011

  𝗔𝗿𝗲𝗮 𝗦𝗮𝗹𝗲𝘀 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿

  I was promoted to lead the $370M West team within a $2.3B global pharmaceutical company focused in respiratory and schizophrenia. Under my leadership, we achieved a significant sales surge through strategic hiring, intensive coaching, and the implementation of elevated accountability standards across all levels.𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:✔ Transformed Sunovion's struggling West area, catapulting 2 asthma / allergy launches to #1 and reviving older key brand, earning back-to-back Area Director of the Year honors. Show less

• 

  Ipsen

  Jan 2012 - Dec 2013

  National Sales Director, US Commercial

  Entrusted with leadership at a $1.5B global innovator in oncology, neuroscience, and rare diseases medicines, I assumed the helm of the Dysport team during a challenging launch. Navigating the competitive landscape against Botox for Cervical Dystonia treatment, I managed a team of 65 across Sales, Marketing, Operations, and Training, with additional oversight for reimbursement and contracting. In this pivotal role, I orchestrated field restructuring, role enhancement, hiring, onboarding, and training, reporting directly to the CEO.𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:✔ Surpassed expectations with consecutive 25% year-over-year (YoY) growth through strategic partnerships with US Centers of Excellence for enhanced disease identification and diagnosis.✔Fully built and led in-house operations and training departments and had initiated and led innovative volume-based contracting with key U.S. institutions. Show less

• 

  Smith & Nephew

  Jan 2014 - Feb 2018

  𝗩𝗶𝗰𝗲 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 Sales, 𝗨𝗦 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝘀 𝗙𝗿𝗮𝗻𝗰𝗵𝗶𝘀𝗲

  I took the helm in transforming Smith & Nephew's Biologics acquisition, orchestrating a successful turnaround. Streamlining operations, I ignited sales and marketing for wound care biologics and devices through an integrated IDN strategy across diverse care settings. Under my leadership, managing a substantial $392M P&L and overseeing 350+ employees, we drove success in this dynamic $4.7B global device and biologic products and services company.𝗦𝗲𝗹𝗲𝗰𝘁𝗲𝗱 𝗔𝗰𝗰𝗼𝗺𝗽𝗹𝗶𝘀𝗵𝗺𝗲𝗻𝘁𝘀 𝗜𝗻𝗰𝗹𝘂𝗱𝗲:✔ Secured partnerships with 15 Specialty Pharmacies, skyrocketing patient access to and compliance with critical medications. Transformed business space from 7% to a 40% revenue powerhouse.✔ Revitalized US sales footprint, restructuring territories for equitable work distribution. Completed full re-segmentation of market accompanied by new prioritization of HCPs and all facilities. Achieved a 4-year net revenue increase from $100M to nearly $400M in net sales. Show less

• 

  IQVIA

  Sept 2018 - Oct 2019

  𝗡𝗼𝗿𝘁𝗵 𝗔𝗺𝗲𝗿𝗶𝗰𝗮, 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗟𝗲𝗮𝗱

  As a driving force at IQVIA, I spearheaded the organization's foray into uncharted territory, successfully establishing a foothold with over 75 biopharma/biotech partners. Through strategic relationships and a compelling value proposition, I propelled remarkable growth within the segment of our $9.74B multinational information technology and clinical research organization.✔ Exceeded $12.5M+ in revenue by building business from scratch, aiding biopharma / biotech in bringing therapies to market through tailored service packages. Show less

• 

  Eisai US

  Nov 2019 - Jan 2023

  I was a key player in a $6.74B global powerhouse, driving innovation in neuroscience, oncology, and rare diseases. I earned a promotion as one of the first three individuals entrusted to build the organization's groundbreaking global flagship franchise from the ground up. Armed with a $32M hiring budget for full-time equivalents (FTEs), I led successful early hiring initiatives and orchestrated effective COVID-19 launch management in 2021.✔ Designed, built, trained, and led 3 customer-facing teams overseeing professional institutional account managers, office-based specialty reps, and an IDN / diagnostic team with each group’s accompanying leadership positions. Co-promoted Aduhlem, the first FDA-approved Alzheimer's treatment in over 20 years.✔ Navigated Aduhelm reimbursement challenges with open communication (town halls, field visits, open door) to achieve an exceptional 95% retention of field personnel compared to partner’s 47% turnover rate.✔ Pioneered the go-to-market strategy for Leqembi, an innovative Alzheimer's infusion therapy. Overcame pre-launch obstacles by designing strategic imperatives, building sales teams from scratch, and setting stage for future Alzheimer's therapy wins.✔ Targeted 5,500 top specialists and 40 top institutions. Created successful patient treatment pathways from diagnosis to infusion with key neurologists, institutions, and infusion centers. Show less My industry leadership and team-building skills were acknowledged when I was recruited to spearhead the launch of Davigo, a groundbreaking insomnia product tailored for neurologists. Subsequently, I was entrusted to concurrently lead the launch of a new, game-changing Alzheimer's franchise.✔ Fully built high-performing Dayvigo launch team through innovative recruitment strategy exceeding 12-week timeline to include hiring of over 350+ individuals from directors to sales representatives and included a virtual staff of 40.✔ Pivoted Dayvigo launch to virtual due to COVID-19 (2020), executing the launch from a home studio for a global broadcast. Hailed as a groundbreaking experience, the launch secured 95% "excellent" ratings, exceeding expectations. Show less

  • 𝗛𝗲𝗮𝗱 𝗼𝗳 𝗦𝗮𝗹𝗲𝘀, 𝗔𝗹𝘇𝗵𝗲𝗶𝗺𝗲𝗿’𝘀 𝗗𝗶𝘃𝗶𝘀𝗶𝗼𝗻: 𝗔𝗱𝘂𝗵𝗹𝗲𝗺 / 𝗟𝗲𝗾𝗲𝗺𝗯𝗶

    Jun 2020 - Jan 2023

  • 𝗦𝗲𝗻𝗶𝗼𝗿 𝗡𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗦𝗮𝗹𝗲𝘀 𝗗𝗶𝗿𝗲𝗰𝘁𝗼𝗿: 𝗗𝗮𝘆𝘃𝗶𝗴𝗼

    Nov 2019 - May 2020
• 

  Patient First HealthCare Consulting, LLC

  May 2023 - now

  Principal & Founder

  Provide consulting services to commercial executives in biopharmaceuticals, medical device and diagnostics specific to launch strategy and execution.

• 

  SteepRock Inc.

  May 2024 - now

  Vice President, Strategic Analytics & Business Development

  At SteepRock Inc., I am dedicated to serving the global life sciences industry exclusively. My role leverages my deep industry knowledge and market understanding, combined with cutting-edge technology, to empower clients to achieve their goals. Key Responsibilities:✔ Collaborate with life sciences organizations to influence and drive their brand and go-to-market strategies.✔ Optimize data-driven decision-making processes throughout the entire product life cycle.✔ Facilitate automation and comprehensive documentation of regulatory compliance.✔ Strengthen Opinion Leader Relationships via the use of AI technologyAreas of Focus:✔ Specialization in Marketing and Commercialization✔ Sales and Key Account Management✔ Medical Affairs✔ Research and Development✔ Business Development and Corporate AffairsMy professional journey at SteepRock has allowed me to engage with multiple organizations across diverse disease states, placing special emphasis on oncology, hematology, CNS therapies, and immunology, including rare and ultra-rare diseases. One particular focus of my work is partnering with organizations that have compounds in Phase III trials to assist and direct in the commercialization and launch of new therapies. Show less